Replies to post #191684 on Biotech Values

[DewDiligence]

ABBV-JNJ—Imbruvica shows statsig PFS/OS in phase-3 trial in first-line CLL/SLL:

http://finance.yahoo.com/news/ibrutinib-imbruvica-improved-survival-treatment-132000678.html

The trial design was Imbruvica head-to-head vs chemotherapy.